Oragenics (OGEN) Liabilities and Shareholders Equity (2010 - 2026)

Oragenics (OGEN) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 93.58% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.4 million (up 144.45% YoY) and the FY2025 annual result came in at $10.1 million, up 583.71% from the prior year.
• Liabilities and Shareholders Equity slipped to $7.5 million in Q1 2026, from $10.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $23.6 million in Q1 2022 to a low of $1.5 million in Q4 2024.
• A 5-year average of $9.3 million and a median of $7.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 70.86% — and 2025, when it soared 583.71%.
• Tracing OGEN's Liabilities and Shareholders Equity over 5 years: stood at $14.8 million in 2022, then plunged by 66.35% to $5.0 million in 2023, then tumbled by 70.35% to $1.5 million in 2024, then soared by 583.71% to $10.1 million in 2025, then declined by 25.61% to $7.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.5 million (Q1 2026), $10.1 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.